Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

September 9, 2013

Primary Completion Date

September 1, 2022

Study Completion Date

September 1, 2022

Conditions
Lymphoid MalignanciesMultiple MyelomaLymphomaHodgkin LymphomaNon-hodgkin Lymphoma
Interventions
DRUG

Pralatrexate

"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2~Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."

DRUG

Romidepsin

"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.~Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."

Trial Locations (3)

10019

Columbia University Irving Medical Center, New York

19111

Fox Chase Cancer Center, Philadelphia

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
lead

Jennifer Amengual

OTHER

NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | Biotech Hunter | Biotech Hunter